secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2021-08-05T23:59:59+00:00
Accession:  0001213900-21-040412
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q2 net loss $12.8M; cash $145M; on track for TARA-002 IND by year-end
-----------------------------------------------------------------------------

- Cash $145M; net loss $12.8M ($1.14/sh) vs $7.1M ($1.22/sh) in Q2 2020.
- R&D expense rose to $5.9M (from $2.5M) on TARA-002; G&A $6.9M (from $4.8M).
- Completed IND-enabling studies for TARA-002 in NMIBC; on track to file IND H2 2021 & start Phase 1.
- GMP comparability for TARA-002 on track for year-end; seeking FDA alignment on LM trial design.
- Appointed Dr. Jane Huang (BeiGene CMO) to Board of Directors in June 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/0001213900-21-040412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390021040412/ea145229-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-21-040412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer